Printer Friendly

Bristol-Myers Squibb enters into agreement to expand access to Reyataz.

M2 PHARMA-June 29, 2011-Bristol-Myers Squibb enters into agreement to expand access to Reyataz(C)2011 M2 COMMUNICATIONS

29 June 2011 - US-based biopharmaceutical company Bristol-Myers Squibb Company (NYSE: BMY) yesterday announced a new agreement to expand access to Reyataz (atazanavir sulfate).

The immunity-from-suit agreement signed with India-based Matrix Laboratories Limited enables the generic company to manufacture and sell atazanavir, as well as stavudine and didanosine, in sub-Saharan Africa and India.

Under the terms of the agreement, Matrix Laboratories will secure World Health Organization (WHO) prequalification for all products covered by the agreement, including pediatric formulations of didanosine and, in the future, atazanavir powder formulation for pediatric use when Bristol-Myers Squibb's product is available. WHO prequalification enables procurement organizations to purchase medicines using funding from United Nations agencies and the Global Fund to Fight AIDS, Tuberculosis and Malaria.

The immunity-from-suit agreement with Matrix Laboratories is the fifteenth agreement that Bristol-Myers Squibb has signed for its HIV medicines, and the fourth for atazanavir. A key component of the agreement is the inclusion of pediatric formulations of the medicines to support the treatment needs of children with HIV.

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jun 29, 2011
Previous Article:Aurel BGC retains 'buy' rating on Sanofi.
Next Article:Shire takes over Advanced BioHealing.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters